摘要
室性心律失常是临床上常见的心律失常,由于常规抗心律失常药物的潜在致心律失常和血液动力学影响等副作用,对结构性心脏病室性心律失常的治疗药物需新的策略。研究发现在心脏病理状态下,心室肌细胞起搏电流活动明显增强,可能是异位节律形成的基础。而起搏电流抑制剂伊伐布雷定作为心率降低药物,越来越多的研究显示伊伐布雷定可减少结构性心脏病中室性心律失常的发生率。本文就起搏电流及其抑制剂伊伐布雷定在室性心律失常治疗方面的基础实验和临床研究作一综述。
Ventricular arrhythmia(VA)is a common clinical arrhythmia.Due to the potential proarrhythmic and hemodynamic side effects of conventional antiarrhythmic drugs,new strategy is required for the treatment of VA in patients with structural heart disease.Previous studies found that in the state of cardiac pathology,the pacemaker current activity of ventricular myocytes was significantly enhanced,which may be the basis for the formation of ectopic rhythm.The pacemaker current inhibitor ivabradine is a clinically widely used heart rate lowering drug,and more and more studies have shown that ivabradine can reduce the incidence of VA in patients with structural heart disease.This review updated the progress in the basic experimental and clinical research regarding pacemaker current and its inhibitor ivabradine in the treatment of VA.
作者
王娟
杨艳敏
谭慧琼
WANG Juan;YANG Yanmin;TAN Huiqiong(Emergency and Intensive Care Center,State Key Laboratory of Cardiovascular Disease,National Center for Cardiovascular Diseases and Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)
出处
《中国循环杂志》
CSCD
北大核心
2023年第5期579-582,共4页
Chinese Circulation Journal
基金
国家科技基础资源调查专项(2018FY100606)
中国医学科学院阜外医院青年科学基金(2022FWQN18)。
关键词
室性心律失常
起搏电流
伊伐布雷定
进展
ventricular arrhythmia
pacemaker current
ivabradine
progress
